Expert second opinion for multiple sclerosis and demyelinating conditions
Radiology Prime provides independent specialist neuroradiology second opinions on brain and spinal MRI for multiple sclerosis and related demyelinating conditions.
Reports are personally prepared within 24 hours by our Clinical Lead, a European-registered consultant neuroradiologist, applying McDonald criteria and MAGNIMS protocols to assess dissemination, activity, and differential, to support discussion with your neurologist.
Why get an independent MS second opinion?
Independent perspective
Interpretations of demyelinating imaging can be shaped by local reporting practice and by whether prior studies were available at the time of the original report. An independent sub-specialty review offers an additional perspective on lesion distribution, activity markers, and change over time, framed as discussion points for your neurology team.
Sub-specialty expertise
MS, NMOSD, MOG antibody-associated disease, and related demyelinating conditions are a core part of our Clinical Lead’s neuroradiology practice. Reports apply McDonald criteria and MAGNIMS protocols to the interpretation and differential discussion.
Comparison across time points
MS is fundamentally a longitudinal diagnosis. When prior imaging is available, our Clinical Lead reviews serial studies side-by-side to assess dissemination in time and changes in disease activity, applying consistent framework-based criteria across visits.
How it works
Get your expert second opinion radiology report in 3 simple steps
Upload your medical scans
Send us your scan images and specific questions, we’ll take care of the rest.
Expert radiologist review
Certified radiologists provide a detailed, easy-to-understand report with your diagnosis and treatment suggestions.
Get results within 24 hours
Receive your report quickly. Talk or message your radiologist directly to discuss your results.
Common diagnostic challenges in demyelinating imaging
An independent review of brain and spinal MRI by our Clinical Lead provides additional framework-based clarity on lesion distribution, disease activity, and differential considerations. Reports are designed to support informed discussion with your neurology team.
Why are demyelinating imaging reports difficult to interpret?
Brain white matter lesions are common and non-specific. Small vessel ischaemic disease, migraine-associated white matter hyperintensities, and age-related changes can share visual features with demyelinating lesions on standard MRI. The distinction often rests on lesion morphology, anatomical distribution, temporal evolution, and comparison with prior imaging — criteria that benefit from dedicated sub-specialty review.
Frequent challenges in MS and demyelinating imaging
Differentiating MS lesions from non-specific white matter hyperintensities
The challenge: White matter lesions on brain MRI are common, particularly with age, and not all are demyelinating.
The reality: Features such as periventricular distribution, juxtacortical and infratentorial location, Dawson’s finger morphology, and the presence of spinal cord lesions may be more consistent with MS than with vascular or migrainous aetiologies. The central vein sign, where available on suitable sequences, can add further discrimination.
Expert value: Our Clinical Lead applies McDonald criteria and MAGNIMS lesion-morphology criteria to support discussion of whether imaging features favour MS or an alternative explanation.
Distinguishing MS from NMOSD and MOG antibody-associated disease
The challenge: NMOSD and MOG-AD can present with imaging findings that overlap with MS but carry different treatment and prognostic implications.
The reality: Longitudinally extensive transverse myelitis, bilateral or longitudinally extensive optic nerve involvement, area postrema lesions, and specific supratentorial patterns may favour NMOSD or MOG-AD over MS. Antibody testing and clinical context remain essential, and the imaging interpretation supports rather than replaces those.
Expert value: Our Clinical Lead assesses imaging features in the context of the McDonald and MAGNIMS frameworks and the NMOSD and MOG-AD consensus diagnostic criteria, to support accurate differential discussion with your neurologist.
Assessing disease activity on follow-up imaging
The challenge: Determining whether MS is stable or active on serial MRI requires careful side-by-side comparison with prior studies. Reports generated without access to all prior imaging may under- or over-state activity.
The reality: New or enlarging T2 lesions and gadolinium-enhancing lesions are the primary imaging markers of disease activity, and their reliable detection depends on comparison protocols consistent with MAGNIMS follow-up guidance.
Expert value: Our Clinical Lead reviews serial studies where available, applying MAGNIMS follow-up protocols to assess change and support informed discussion of treatment response with your neurologist.
MS and demyelinating conditions reviewed by our Clinical Lead
Patients often seek a second opinion for these specific clinical scenarios:
Diagnosis support
Clinically isolated syndrome (CIS): Independent MRI review applying McDonald criteria to assess dissemination in space and time, to support diagnostic workup discussion with your neurologist.
Radiologically isolated syndrome (RIS): Assessment of incidental white matter findings in asymptomatic patients, with framework-based opinion on features that may warrant further neurological follow-up.
Relapsing-remitting MS workup: Structured reporting of brain and spinal MRI against McDonald criteria to support diagnostic conversations with your treating team.
Related demyelinating conditions
Neuromyelitis optica spectrum disorder (NMOSD): Review of brain, spinal cord, and optic nerve imaging for features that may favour NMOSD over MS, applying consensus diagnostic criteria.
MOG antibody-associated disease (MOGAD): Assessment of imaging features that may be more consistent with MOGAD than with MS or NMOSD, to support antibody-informed discussion.
Acute disseminated encephalomyelitis (ADEM): Structured review of imaging features in suspected monophasic demyelinating illness.
Follow-up and disease activity
Annual surveillance MRI: Side-by-side comparison with prior studies applying MAGNIMS follow-up protocols to assess change.
New T2 and gadolinium-enhancing lesion assessment: Independent review of disease activity markers to support treatment discussion with your neurologist.
Treatment response review: Radiology support for disease-modifying therapy response discussions, framed as imaging-based discussion points rather than clinical directives.
PML surveillance in treated patients: Focused review of imaging features that may raise the possibility of progressive multifocal leukoencephalopathy in patients on specific disease-modifying therapies. If such features are identified, the report explicitly recommends urgent discussion with the treating neurologist.
Related demyelinating conditions
Small vessel ischaemic disease: Framework-based discussion of imaging features that may favour vascular over demyelinating aetiology.
Migraine-associated white matter hyperintensities: Assessment of non-specific lesions in the context of headache history.
Autoimmune encephalitis and other inflammatory CNS conditions: Review of imaging features that may raise the possibility of alternative inflammatory aetiologies.
CNS vasculitis: Assessment of imaging features that may be more consistent with vasculitic than demyelinating pathology.
View a Sample Neuroradiology Report
Transparency is key to trust. View a redacted sample of an second opinion report. In this case, the MRI findings were interpreted as more consistent with a non-demyelinating process rather than active multiple sclerosis.
Frequently asked questions
A second-opinion radiology report is an additional informational input, not a diagnostic decision in itself. Our Clinical Lead applies McDonald criteria and MAGNIMS protocols to your brain and spinal MRI and provides an independent structured opinion on lesion distribution, activity, and differential considerations. The final diagnostic decision, including any revision to an MS diagnosis, rests with your neurologist, who integrates imaging with clinical examination, CSF analysis, antibody testing, and disease course. The report is designed to support that discussion with your treating team.
Yes — the report is intended to be shared with your neurologist. It is structured for peer-to-peer clinical use, with specific framework citations (McDonald, MAGNIMS) and cross-referenceable findings, alongside a plain-language summary for patients. The radiology report is personally signed by our Clinical Lead under her full name and credentials, as any hospital-generated radiology report would be. We encourage you to share it directly with your neurology team.
No. In most regions, patients may independently request a radiology second opinion.
Our service provides an independent subspecialty radiology review of your existing MRI or CT imaging. This evaluation is designed to support and not replace your treating physician’s clinical assessment.
We encourage discussing your second-opinion report with your doctor to determine the most appropriate next steps.
Second opinions are typically delivered within 24 hours, and many cases are completed sooner. Our radiology team prioritizes timely reviews to help you receive additional diagnostic insight as efficiently as possible.
Our technical support team can assist if you experience difficulty uploading your images. The website chat feature is available to help answer technical questions during the submission process.
Follow-up questions are welcome after your report is delivered. If clarification is needed, you may submit questions to the radiologist who performed your review. This process is designed to help address outstanding points and support discussion with your treating physician.
You receive a detailed review of your MRI or CT scan prepared by experienced European radiologists. Beyond listing findings, the report explains how the imaging observations relate to the clinical information you provide. Each report follows established radiology standards and includes a clear summary to support discussion with your treating physician.
We provide a comprehensive clinical report written for your treating physicians, along with a clear plain-language summary. This approach is designed to help you better understand the reasoning behind the imaging findings while supporting discussion with your doctor.